Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases : Observations from a VALDIG multicenter study
Pérez Campuzano, Valeria (Hospital Clínic i Provincial de Barcelona)
Rautou, Pierre-Emmanuel (Centre de Référence des Maladies Vasculaires du Foie)
Marjot, Thomas (University of Oxford (Regne Unit))
Praktiknjo, Michael (University Hospital Bonn (Bonn, Alemanya))
Alvarado-Tapias, Edilmar (Institut de Recerca Sant Pau)
Turco, Laura (IRCCS AziendaOspedaliero-Universitaria di Bologna(Itàlia))
Ibáñez-Samaniego, Luis (Hospital General Universitario Gregorio Marañón)
González-Alayón, C. (Hospital Universitario de Canarias (La Laguna))
Puente, Ángela (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Llop, Elba (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Simon-Talero, Macarena (Hospital Universitari Vall d'Hebron)
Álvarez-Navascués, Carmen (Hospital Universitario Central de Asturias)
Reiberger, Thomas (Medical University of Vienna)
Verhelst, Xavier (Universitair Ziekenhuis Gent(Bèlgica))
Tellez, Luis (Hospital Universitario Ramón y Cajal (Madrid))
Bergmann, JJohanna Birte (German Center for Infection Research (DZIF)(Alemanya))
Orts, Lara (Hospital Clínic i Provincial de Barcelona)
Grassi, Giuseppe (Hospital Clínic i Provincial de Barcelona)
Baiges, Anna (Hospital Clínic i Provincial de Barcelona)
Audrey, Payance (Université Paris-Cité(França))
Trebicka, Jonel (University of Münster(Alemanya))
Villanueva, Càndid (Institut de Recerca Sant Pau)
Morelli, Maria Cristina (IRCCS AziendaOspedaliero-Universitaria di Bologna(Itàlia))
Murray, Sam (University of Oxford(Regne Unit))
Meacham, Georgina (University of Oxford(Regne Unit))
Luetgehetmann, Marc (German Center for Infection Research (DZIF)(Alemanya))
Schulze zur Wiesch, Julian (University Medical Center Hamburg-Eppendorf(Alemanya))
García-Pagán, JC (Hospital Clínic i Provincial de Barcelona)
Barnes, Eleanor (University of Oxford(Regne Unit))
Plessier, Aurélie (Université Paris-Cité(França))
Hernández-Gea, Virginia (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed. Results: A total of 898 patients from 14 European centers - part of the VALDIG network - were included, 872 (97. 1%) patients received two vaccine doses (fully vaccinated), and 674 (75. 1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5. 9%) were re-infected. Of the 747/898 patients who were not previously infected, 11. 2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3. 5%) patients had thromboembolic events and 21 (2. 3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses. Conclusion: Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated. Impact and implications: Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported.
Ajuts:	Instituto de Salud Carlos III PI20/00569 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01115
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 vaccine ; Vascular liver disease ; Portal thrombosis
Publicat a:	JHEP Reports, Vol. 6 Núm. 12 (december 2024) , p. 101191, ISSN 2589-5559

DOI: 10.1016/j.jhepr.2024.101191
PMID: 39583091

10 p, 926.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats